Robinson David Wayne 4
4 · OCULAR THERAPEUTIX, INC · Filed Jan 26, 2026
Research Summary
AI-generated summary of this filing
Ocular Therapeutix (OCUL) CCO David W. Robinson Receives RSU and Option Awards
What Happened
David Wayne Robinson, Global Chief Commercial Officer of Ocular Therapeutix (OCUL), was granted equity awards on January 21, 2026: 136,000 restricted stock units (RSUs) and a 416,000-share derivative option award. The Form 4 records $0 paid at grant for both awards (standard for equity grants). These are grants/awards (not purchases or sales) and therefore do not represent open‑market buying or selling.
Key Details
- Transaction date: January 21, 2026; Form 4 filed January 26, 2026 (filed five days after the grant date; appears later than the typical 2-business‑day Form 4 deadline).
- Awards: 136,000 RSUs (each RSU = right to one share) and a 416,000-share derivative option grant. Both reported as Award/Grant (code A).
- Price at grant: $0.00 reported (no cash paid by the reporting person at grant).
- Shares owned after transaction: not specified in the provided filing information.
- Vesting (from footnotes): RSUs vest over 3 years — 1/3 on the one‑year anniversary of the grant and 1/3 each year thereafter. The option vests over 4 years — 25% on the one‑year anniversary of the reporting person’s first date of employment, then monthly over the following three years.
- No indication of immediate sale, tax withholding, 10b5‑1 plan, or other special conditions in the provided notes.
Context
- RSUs: when they vest, each RSU converts into one share (subject to any withholding), so value to the insider depends on OCUL’s share price at vesting.
- Options/derivatives: this was a grant of an option-type award (derivative). The Form 4 shows the grant but does not indicate exercise or sale — it’s not an exercise or cashless transaction. Exercise price and other option terms beyond vesting schedule are not detailed in the provided summary.
- Interpretation for investors: equity grants to executives are common for compensation/retention and align insider interests with shareholders but are not direct signals of buying or selling. The late filing may be noteworthy for compliance tracking.
Insider Transaction Report
Form 4
Robinson David Wayne
Global CCO
Transactions
- Award
Common Stock
[F1]2026-01-21+136,000→ 136,000 total - Award
Stock Option (Right to Buy)
[F2]2026-01-21+416,000→ 416,000 totalExercise: $11.42Exp: 2036-01-20→ Common Stock (416,000 underlying)
Footnotes (2)
- [F1]On January 21, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2019 Inducement Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
- [F2]This option was granted on January 21, 2026 and vests over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the reporting person's first date of employment and the remainder vesting in equal monthly installments over the three years after such date.
Signature
/s/ Todd Anderman, Attorney-in-Fact for David Wayne Robinson|2026-01-26